Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

HPV vaccine indicated for treating anal cancers


The European Commission has approved the use of Gardasil – the quadrivalent human papillomavirus vaccine – for preventing anal precancerous lesions and anal cancers that are causally related to certain oncogenic HPV types in men and women.

It is already indicated for the prevention of HPV-related cervical cancer and premalignant genital lesions in females aged nine and over. 

The vaccine, which is manufactured by Sanofi Pasteur MSD, protects against HPV types 6, 11, 16, 18.

This new indication “acknowledges the efficacy of Gardasil, targeting the high-risk HPV types 16 and 18 which cause the vast majority of anal cancers”, said Sanofi in a statement.



Readers' comments (2)

  • It should be given to both men and women anyway

    Unsuitable or offensive? Report this comment

  • It should be given to both men and women

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs